Investigational drug · Phase 3
4D-150
Also called: 3E10 vg, eye, 3x10^10 vg
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
5
Any phase or sponsor naming "4D-150"
First trial start
2021
Dec 9, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "4D-150", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neovascular Age-Related Macular Degeneration (nAMD)
- Diabetic Macular Edema (DME)
- Neovascular (Wet) Age-Related Macular Degeneration
- Diabetic Macular Edema
- Diabetic Retinopathy
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "4D-150" as an intervention, largest first.
- A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).Pivotal-lookingRecruiting
4D Molecular TherapeuticsIndustry
NCT07867080 · 514 participants (planned) · Start Sep 18, 2026 · Primary completion Jan 2029
Drug: 4D-150 IVT (3x10^10 vg); EYELEA ® (aflibercept) Injection 2 mg (0.05mL) · For: Diabetic Macular Edema (DME)
Sites: Scottsdale, Arizona; Encino, California; Fullerton, California · 95 sites in all
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPivotal-lookingActive, not recruiting
4D Molecular TherapeuticsIndustry
NCT06864988 · 480 participants (planned) · Start Mar 3, 2025 · Primary completion Jun 2027
Drug: 4D-150 IVT (3E10 vg/eye); EYLEA® (aflibercept) Injection 2 mg (0.05mL) · For: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Scottsdale, Arizona; Springdale, Arkansas · 94 sites in all
- Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPivotal-lookingRecruiting
4D Molecular TherapeuticsIndustry
NCT07064759 · 480 participants (planned) · Start Jul 22, 2025 · Primary completion Nov 2027
Drug: 4D-150 IVT (3E10 vg/eye); EYLEA® (aflibercept) Injection 2 mg (0.05mL) · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Scottsdale, Arizona; Sun City, Arizona; Tucson, Arizona · 126 sites in all
- 4D-150 in Patients With Neovascular (Wet) Age-Related Macular DegenerationPivotal-lookingRecruiting
4D Molecular TherapeuticsIndustry
NCT05197270 · 215 participants (planned) · Start Dec 9, 2021 · Primary completion Mar 2027
Drug: 4D-150 IVT; Aflibercept IVT · For: Neovascular (Wet) Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Oxnard, California; Sacramento, California · 26 sites in all
- 4D-150 in Patients With Diabetic Macular EdemaActive, not recruiting
4D Molecular TherapeuticsIndustry
NCT05930561 · 72 participants (planned) · Start Aug 9, 2023 · Primary completion Feb 28, 2029
Drug: 4D-150 IVT; Aflibercept IVT · For: Diabetic Macular Edema; Diabetic Retinopathy
Sites: Hagerstown, Maryland; Eugene, Oregon; Erie, Pennsylvania · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Visual behaviour in acute stress during simulated and on-road driving.
Bakhchina A, Arutyunova K, Burashnikov E, et al. · Stress 2027
- Sleep EEG oscillations and synaptic plasticity in memory consolidation across NREM and REM sleep.
Chen Y, Zhao M, Cao X, et al. · Dialogues Clin Neurosci 2027
- Benefit of Linked-Color Imaging in Artificial Intelligence-Assisted Diagnosis of Early Gastric Cancer: A Pilot Study With Propensity Score Adjustment.
Mohamed AN, Minoda Y, Maruoka R, et al. · DEN Open 2027
- CRISPR-based point-of-care platform for EBV DNA screening and monitoring in nasopharyngeal cancer plasma.
Zhang J, Huang H, Xu J, et al. · Talanta 2027
- From ear to eye: Transparent alkali-treated autologous cartilage for corneal stromal regeneration.
Yang Y, Li Y, Wang Z · Biomaterials 2027
- Dual-mode colorimetric sensing of bilirubin using a PDDA@peroxomolybdate composite: A spectrophotometric platform and cost-effective cotton-swab sensor for point-of-care testing.
Avan AA, Filik H, Kucur M, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
Also in development for Neovascular Age-Related Macular Degeneration (nAMD)
- OTX-TKIaxitinib implantPhase 33 trials
Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)
- QL1207HPhase 31 trial
Qilu Pharmaceutical Co., Ltd. · Neovascular Age-Related Macular Degeneration (nAMD)
- KHK4951Phase 22 trials
Kyowa Kirin Co., Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.